Opinion|Videos|October 1, 2024
Multi-Modal Treatment Strategy for HFmrEF and HFpEF
Author(s)Javed Butler, MD, MPH, MBA
Javed Butler, MD, MPH, MBA, discusses the additional benefits of combining finerenone with sodium-glucose cotransporter-2 inhibitors for treating heart failure (HF) with midrange ejection fraction (EF) and HF with preserved EF as well as how a multimodal approach used in HF with reduced EF can be adapted for managing these conditions.
Advertisement
Video content above is prompted by the following:
- What additional benefits does adding finerenone offer when combined with sodium-glucose cotransporter-2 inhibitors for the treatment of heart failure with midrange ejection fraction (HFmrEF) and HF with preserved EF (HFpEF)?
- When considering the multimodal approach for the treatment of HF with reduced EF, how can that strategy now be implemented for the management of HFmrEF and HFpEF?
- What results were presented?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Advertisement
Advertisement
